Challenges in the assessment, diagnosis and management of severe, difficult-to-control asthma are increasingly regarded as clinical needs yet unmet. The assessments required to determine asthma severity, comorbidities and confounding factors, disease phenotypes and optimal treatment are among the controversial issues in the field. The respiratory care experts' input forum (RC-EIF), comprised of an Iranian panel of experts, reviewed the definition, appraised the available guidelines and provided a consensus for evaluation and treatment of severe asthma in adults. A systematic literature review followed by discussions during and after the forum, yielded the present consensus. The expert panel used the appraisal of guidelines for research and evaluation-II (AGREE-II) protocol to define an initial locally-adapted strategy for the management of severe asthma. Severe asthma is considered a heterogeneous condition with various phenotypes. Issues such as assessment of difficult-tocontrol asthma, phenotyping, the use of blood and sputum eosinophil count, exhaled nitric oxide to guide therapy, the position of anti-IgE antibody, methotrexate, macrolide antibiotics, antifungal agents and bronchial thermoplasty as well as the use of established, recently-developed and evolving treatment approaches were discussed and unanimously agreed upon in the panel. A systematic approach is required to ensure proper diagnosis, evaluate compliance, and to identify comorbidities and triggering factors in severe asthma. Phenotyping helps select optimized treatment. The treatment approach laid down by the Global Initiative for Asthma (GINA) needs to be followed, while the benefit of using biological therapies should be weighed against the cost and safety concerns.
THE RESPIRATORY CARE EXPERTS' INPUT FORUM AND SEVERE ASTHMA
When a patient requires high intensity inhaled corticosteroids (HICS) and a long-acting beta-agonist (LABA) and/or systemic corticosteroids (CS) to prevent his/her asthma from becoming uncontrollable, or if the symptoms remain uncontrollable despite adequate therapy, the condition is referred to as severe, difficult-tocontrol asthma (1) . According to the GINA, asthma severity is assessed retrospectively from the level of treatment required to control symptoms and exacerbations. the prevalence is increasing in major cities (6) (7) (8) (9) (10) (11) . Given the health burden of the disease, the national asthma and allergy strategy based on GINA and other international widely-referenced guidelines needs to be developed and implemented. The importance and necessity of having comprehensive national guideline for asthma should be further emphasized with certain criteria for referral.
Beside the recently drafted and approved national guideline for asthma care addressing level-one and -two healthcare providers (general practitioners, family physicians and internists), a solid locally-adapted approach to subcategories of asthmatics and severe asthma patients needs to be defined.
Despite the fact that many asthmatic patients may be effectively controlled using the available medications, there is a subset of patients who remain refractory (12). These patients have considerable health expenditures (13, 14).
There is much to be answered regarding the possible underlying mechanisms governing asthma unresponsive to treatment and the best approach to manage such patients. The definitions of severe/refractory asthma were agreed upon as variations of such patients had been adopted previously (15). Just recently, an AmericanEuropean task force comprised of clinicians and scientists with special expertise in severe asthma was established to revisit previous definitions, define possible phenotypes of severe asthma, propose methods for its evaluation and provide recommendations on treatment (4) . Severe asthma is regarded as a heterogeneous disease, with various phenotypes. The investigations suggested phenotypic biomarkers and targeted biologic therapies which partly succeeded to show efficacy (4) . After defining a list of contextual questions, a series of plenary talks and interactive round table discussion were conducted; the AGREE-II protocol was employed to appraise international guideline statements for local implementation. The AGREE-II protocol which can be applied to any set of guidelines in health care such as health promotion, public health, screening, diagnosis, treatment or interventions is perhaps regarded as one of the simplest methods of appraising and customizing international guidelines for locally-adapted strategies (5).
MATERIALS AND METHODS

A. The expert panel composition and consensus
The section moderators of this EIF proposed several questions related to the definition and characteristics, diagnosis and treatment of severe asthma. These contextual questions (CQs) were defined two weeks prior to the meeting with key CQs on the diagnosis and treatment of severe asthma isolated and ranked by priority.
Five CQs were selected to be explicitly discussed to provide clinical insight into optimal, evidence-based care in severe asthma. Obesity is another comorbidity linked with severe and difficult-to-control asthma. Its association with asthma may largely depend on the age at onset (70, 71) .
Sadly, the worldwide health threat, smoking, has become more popular among youngsters in our community over the past decades (72) (73) (74) (75) (76) (77) . It can make asthma more difficult-to-control (78) . The inflammatory processes seem to be altered in smokers leading to an attenuated response to CS (79, 80) . Some reports have suggested testing the urinary and salivary cotinine in asthmatic patients as the test often reveals evidence of exposure to second-hand smoke (81) (82) (83) . On the other hand, environmental factors such as ozone levels are directly linked with asthma outcomes in urban populations (84, 85) . Given the critical importance of air pollution in our major cities, well-designed studies on environmental exposures and severe asthma are urgently required.
The prevalence of anxiety and depression in adults with severe asthma has reached 50% in some reports (47, [86] [87] [88] . Such conditions are frequently subject to oversight.
Therefore, when indicated, a proper psychiatric assessment and providing the required care is imperative (89) . There Lastly, when addressing asthma-related comorbidities, therapy-induced issues pertaining to the overuse of inhaled and systemic CS should also be considered (91) (92) (93) .
ii. Experts' statement 
b. Inhaled and oral CS therapy
The threshold daily doses of ICSs are outlined in Table   1 . These are higher than the usual doses required to achieve maximal therapeutic effects in milder asthma.
There is individual variation in dose-efficacy of ICS with evidence suggesting that greater ICS doses may show greater efficacy in severe asthma (132, 133) . Together, there seem to be insufficient data to support higher doses (over 2000 mcg/day) of ICS and ultra-fine particle ICS in severe asthmatics.
To control severe asthma, physicians may need to even quadruple the dose of ICS in some cases (134) . In severe asthma, the dose and treatment duration of beta-agonist agents frequently exceed those recommended by guidelines and this makes it hard to comment on the presumably safe upper dose limit. Some case reports have indicated that a medically-supervised decrement in the dose of beta-agonists in some severe adult asthma patients who take excessive beta-agonists has led to an improved asthma control (149) .
To prevent the overuse of beta-agonists in severe asthma patients, especially in those showing side effects including tremor and palpitations and to help control asthma exacerbations, the use of ipratropium bromide aerosols is a supported option (150, 151) . Although less effective, it is considered safer than beta-agonists and can be used as-needed during the day. The routine use of nebulizers has not been supported owing to a relative inefficiency in drug delivery. On the other hand, the use of pressurized metered dose inhalers (pMDI) with a spacer is recommended in severe asthma and upon exacerbations (152) .
d. Slow-release theophylline
In moderate asthma, symptom control can be achieved when theophylline is added to ICS (113) . Theophylline (plus low dose ICS) has also been shown to enhance peak expiratory flow rates and lead to asthma control in smoking asthmatics, who demonstrated CS insensitivity (153) . It is then plausible that theophylline improves CS insensitivity in some cases. Nevertheless, no such investigation has been done in adults with severe asthma.
e. Modifiers of the leukotriene pathway
The well-established anti-inflammatory activity of 
Specific approaches directed towards severe asthma
Until recently, research endeavors to investigate the optimized treatments for severe asthma were trivial. This landscape is however rapidly changing now. Several welldesigned trials are ongoing to investigate the novel molecular-targeted therapies in the adult population suffering from severe asthma The evidence on safety profile of these new treatment options is however scant and continues to evolve (97, 98, 104, (170) (171) (172) (173) (174) (175) (176) . Table 2 .
ii. Experts' statement
The combination of ICS and one or two additional 112. Incorvaia C, Ridolo E. In the strategies to prevent asthma exacerbations, allergic asthma needs specific treatment. Curr
